Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF

Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to reduce the risk of cardiovascular death or heart failure hospitalization and improve symptoms among patients with chronic heart failure with reduced ejection fraction compared to enalapril, the gold standard...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	JACC. Heart failure 2020-10, Vol.8 (10), p.800-810
Hauptverfasser:	Docherty, Kieran F, Vaduganathan, Muthiah, Solomon, Scott D, McMurray, John J V
Format:	Artikel
Sprache:	eng
Schlagworte:	Aminobutyrates Angiotensin Receptor Antagonists - therapeutic use Biphenyl Compounds Drug Combinations Heart Failure - drug therapy Humans Neprilysin - therapeutic use Stroke Volume Valsartan - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!